BioAge Labs Inc.

NASDAQ: BIOA · Healthcare · Biotechnology

PublicHQ Emeryville, CA · AlamedaCIK 0001709941Reports USD

#642 of 1,394 Healthcare companies by revenue

EA Score

50D

FH 58DQ 38GM —SS 46

v0.1 · 55/100 weight · provisional

↑ Altman-Z, balance-sheet leverage · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

$10.3M

Rev growth YoY (TTM)

+611.0%

Net income (FY)

-$80.6M

Employees

Market cap

$945.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$9.0M$9.0M2025

Net income-$80.6M-$80.6M2025

Operating income-$92.8M-$92.8M2025

Total assets$294.9M$294.9M2025

Liabilities$22.8M$22.8M2025

Equity$272.1M$272.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

BioAge Labs Inc. booked $9.0M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -896.1% net margin.

Peers · Healthcare

Janux Therapeutics, Inc.54D LB Pharmaceuticals Inc Common Stock——Arbutus Biopharma Corp61C Replimune Group, Inc.——

Neighbors

Alameda →

Lam Research Corporation$18.4B85A Ross Stores, Inc.$22.8B79B+Block, Inc.$24.2B69B PG&E Corporation$24.9B70B Workday, Inc.$9.6B79B+Veeva Systems Inc.$3.2B86A

Key facts

CEOKristen Fortney

SectorHealthcare

IndustryBiotechnology

HeadquartersEmeryville, CA

ExchangeNASDAQ: BIOA

Employees61

IPO date2024-09-26

Latest filings

8-K2026-06-12 10-Q2026-05-08 8-K2026-05-08 DEF 14A2026-04-21 10-K2026-03-24 8-K2026-03-24 8-K2026-01-22 8-K2026-01-20

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.